Abstract
Rapid progress in cystic fibrosis research affords the possibility of halting the progress of the lung disease. We used data from 215 patients who had sputum cultures negative for Burkholderia cepacia, at least one outpatient pulmonary function test during 1990, and at least one test a year later to estimate the number of subjects and study duration required to demonstrate that a hypothetical treatment reduces the rate of decline of forced expiratory volume in 1 s (FEV1) to zero. Mean rate of decline of FEV1 (percent predicted) was about 2% predicted per year. Variability decreases with increasing time of observation. For a 1-y study, with α = 0.05 and β = 0.20, over 550 patients must complete the study in each group to show that a treatment halts pulmonary decline. For a 2-y study, 86 subjects in each group are required, and for 4 y, 65. Increasing the number of data points used to determine the rate of decline of FEV1 had only small effect on sample size. Use of pulmonary function data collected at regular intervals for research purposes did not alter these conclusions. Higher initial FEV1 was associated with a greater rate of decline, and among patients with initial FEV1 >60% predicted, younger subjects had a faster decline than did older subjects. Thus, fewer subjects will be required to detect a complete halt in progression of lung disease if the patients are young and have mild pulmonary disease.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- CF:
-
cystic fibrosis
- FEV1:
-
forced expiratory volume in 1 s
References
Davis PB 1994 Evolution of therapy for cystic fibrosis. N Engl J Med 331: 672–673
Fitzsimmons SC 1993 The changing epidemiology of cystic fibrosis. J Pediatr 122: 1–9
Ramsey BW, Boat TF 1994 Outcome measures for clinical trials in cystic fibrosis. J Pediatr 124: 177–192
Kerem E, Reisman J, Corey M, Canny GJ, Levison H 1992 Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326: 1187–1191
Wagener JS, Taussig LM, Burrows B, Hernried L, Boat T 1980 Comparison of lung function and survival patterns between cystic fibrosis and emphysema or chronic bronchitis patients. In: Sturgess JM (ed) Perspectives in Cystic Fibrosis: Proceedings of the Eighth International Cystic Fibrosis Congress, Toronto, May 26-30, 1980. Canadian Cystic Fibrosis Foundation, Toronto, pp 236–245
Cooper PJ, Robertson CF, Hudson IL, Phelan PD 1990 Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 8: 16–22
Nickerson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Robertson G 1980 Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 122: 859–866
Corey M, Levison H, Crozier D 1976 Five to seven-year course in pulmonary function in cystic fibrosis. Am Rev Respir Dis 114: 1085–1092
Konstan MW, Byard PJ, Hoppel CL, Davis PB 1995 Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332: 848–854
Standardization of spirometry-1987 update: statement of the American Thoracic Society 1987 Am Rev Respir Dis 136: 1258–1298
Knudson RJ, Lebowitz MD, Holbert CL, Burrows B 1983 Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725–734
Knowles MR, Hohneker KW, Zhou ZQ, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR, Grossman M, Wilson JM, Johnson LG, Boucher RC 1995 A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333: 823–831
Crystal RG, McElvaney NG, Rosenfeld MA, Chu C-S, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C 1994 Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8: 42–51
Hay JG, McElvaney NG, Herena J, Crystal R 1995 Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 6: 1487–1496
Knowles MR, Clarke LL, Boucher RC 1991 Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325: 533–538
Eidelman O, Guay Broder C, van Galen PJ, Jacobson KA, Fox C, Turner RJ, Cabantchik ZI, Pollard HB 1992 A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA 89: 5562–5566
Gribkoff VK, Champigny G, Barbry P, Dworetzky SI, Meanwell NA, Lazdunski M 1994 The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J Biol Chem 269: 10983–10986
Kelley TJ, Al-Nakkash L, Drumm ML 1995 CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 13: 657–664
Ellis DA, Thornley PE, Wightman AJ, Walker M, Chalmers J, Crofton JW 1981 Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax 36: 659–664
Kerem E, Corey M, Gold R, Levison H 1990 Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116: 714–719
Dankert-Roelse JE, te Meerman GJ 1995 Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre. Thorax 50: 712–718
Gan K-H, Veeze HJ, Van den Ouweland AMW, Halley DJJ, Scheffer H, VanderHout A, Overbeek SE, DeJongste JC, Bakker W, Heijerman HGM 1995 A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 333: 95–99
Kovesi T, Corey M, Levison H 1993 Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis 148: 1266–1271
Author information
Authors and Affiliations
Additional information
Supported by National Institutes of Health Grant P30 DK27651 and by a Research Development Program Grant from the Cystic Fibrosis Foundation.
Rights and permissions
About this article
Cite this article
Davis, P., Byard, P. & Konstan, M. Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis. Pediatr Res 41, 161–165 (1997). https://doi.org/10.1203/00006450-199702000-00001
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-199702000-00001
This article is cited by
-
Gene therapy for cystic fibrosis: an example for lung gene therapy
Gene Therapy (2004)
-
Macrolides in Cystic Fibrosis
American Journal of Respiratory Medicine (2002)
